10506693 - GAU: 1634 Express Meil No EM245183239UI

. Approved for use Programmer Carden's Edit 2010.

U.S. Passed ann Thademan Citics, U.S. Department on the Programmer Carden's Edit 2010.

U.S. Passed ann Thademan Citics, U.S. Department of the Programmer Citics, U.S. Department of the Conference Citics, U.S. Department of the Con

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

WO 95/15373

WO 95/16792

WO 96/40995

WO 97/45560

WO 97/46705

Sheet

of 6

Complete if Known Application Number 10/506,693 Filing Date April 21, 2005 First Named Inventor Kurt Berlin Art Linit 1634 Examiner Name Katherine D. Salmon Attorney Docket Number 47675-86

Examiner	Cite	Document Number	Publication	n Date		Name of Patentee or	Pages, Columns, Lines, Wh Relevant Passages or Relev	ere
initiate) No.1		Number-Kind Code ³ (if known)	MM-OD-YYYY		Applicant of Cited Cocument		Figures Appear	
/1(0)		US-4683195	07-28-198	37	Mullis et a	ł		
		US-4683202	07-28-198	37	Mullis			
		US-4800159	01-24-195	39	Mullis et a	Ł.		
		US- 5498699	03-05-1996		Sorenson			
		US- 5552277	09-03-199	36	Nelson et	al.		
		US-5691146	11-25-199	37	Mayrand			
US-		US- 5723591	03-03-199	03-03-1998 Livak et al.				
		US-5876930	03-02-1999		Livak et al.			
		US- 5952170	09-14-199	9	Stroun et	al.		
		US- 6156504	12-05-200	00	Gocke et	al.		
		US- 6214556	04-10-200)1	Olek et al			
		US- 6228592	05-06-200)1	Tsuji et al			
1/		US- 6265171	07-24-200)1	Herman e	t al.		
¥		US-6331393	12-18-20)1	Laird et al			
	M. s		FOREIC	IN PAT	ENT DOCU	MENTS		
		Foreign Patent Document					Pages, Columns, Lines,	
xaminer nitials*	Cite No.	Country Code ² -Number ⁴ -Kind Code	⁴ (il knawn)	MM-E	eted noits	Name of Patentee or Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	7

V		WO 96/06980	03-05-1998	Johns Hopki School of Me	ns University edicine		
······							
Examiner Signature		/Kathorina Salmon/			Date Considered	09/30/2008	

06-08-1995

06-22-1995

12-19-1996

12-04-1997

12-11-1997

McGill University

Trustees of Dartmouth

North Shore University Hospital Research Corp.

Johns Hopkins University School of Medicine Johns Hopkins University

Stroun et al.

Callege

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant, Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Petent Documents of woman to a popular support of the proposal properties of the a check mark here it English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commistis on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2

10506693 - GAU: 1634

PTO/SB/084 (08-03)
Approved for use through 07/31/2006. OMS 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
on existedion of information uniters if contains a white OMS control number.

Substitute for form 1449/PTO	
INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are requir

of 6

(Use as many sheets as necessary)

Sheet

ASSE TO A CARROCOUN OF SHOWING	Elega II Cortaina a Fond Certo Carto O Hongo.			
Complete if Known				
Application Number	10/506,693			
Filing Oate	April 21, 2005			
First Named Inventor	Kurt Berlin			
Art Unit	1634			
Examiner Name	Katherine D. Salmon			
Attorney Docket Number	47675-86			

		Foreign Palent Document				Pages, Columns, Lines,	
xaminer stiels*	Cite No.1	Country Code ³ -Number ³ -Kind Code ³ (# known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Doo		Where Relevant Passages Or Relevant Figures Appear	l r
/KS/		WO 98/56952	12-17-1998	University of Southe California	m		
		WO 99/28498	06-10-1999	Epigenomics GmbH			<u></u>
J		WO 00/70090	11-23-2000	University of Southe California	rn		
V		WO 02/072889	09-19-2002	Epigenomics AG			
· .		NON PAT	ENT LITERATURE	DOCUMENTO .		am though managable insumal	
xaminer visis*	Cite No.	senal, sym	posium, catalog, etc.),	date, page(s), volume- ir country where publish	seue	, (book), (10goz.110, john 40)	Τ,
KS/		ADORJAN et al., "Tumour class prediction Acids Research, 2002, p. e21, Volume 36	n and discovery by n), No. 5 (9 pages)	icroarray-based DNA	methylatic	on analysis," Nucleic	
AGATHANGGELOU et al., "Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breas ovarian tumours," Oncogene, 2001, pp. 1509-1518, Valums 20				.3 in lung, breast and			
AHRENDT et at., "Molecular Detection of Tumor Cells in Bronchostveolar Lavags Fluid From Patients With Euror Cancer," Journal of the National Cancer Institute, February 17, 1999, pp. 332-339, Volume 91, No. 4				Patients With Early Stage ne 91, No. 4			
		ANKER et al., "Detection of circulating tu Metastasis Reviews, 1999, pp. 65-73, Vg		od (plasma/serum) of c	ancer pati	ents,* Cancer and	
		ANKER at al., "K-ras Mutations Are Foun Gastroenterology, 1997, pp. 1114-1120,"	d in DNA Extracted i Volume 112	from the Plasma of Pa	tients Witt	h Colorectal Cancer,*	
		BAYLIN et al., "Abnormal Patterns of DN. Progression," Cancer Cells, October 199	A Methylation in Hun 1, pp. 383-390, Volu	en Neoplesia: Patenta ne 3, No. 10	at Conseq	uences for Tumor	
		BOTEZATU et al., 'Genetic Analysis of D Sequences from Cells Dying in an Organ	NA Excreted in Unin- ism,* Clinical Chemis	a: A New Approach for try, 2000, pp 1078-10	Detecting 84, Volum	Specific Genomic DNA se 46, No. 8	
		BRET et al., "Quantitation of blood plasm Volume 61	a DNA as an index o	f in vivo cytotoxicity,* 1	loxicology	, 1990, pp. 283-292,	
	BYUN et al., "Frequent Epigenetic Inactivation of RASSF1A by Aberrant Promoter Hypermethylation in Human Ges Adenocarcinema," Cancer Research, October 1: 2001, pp. 7034-7038, Volume 61					ylation in Human Gestric	
		CAIRNS et al., "Molecular Detection of P Research, September 2001, pp. 2727-27		ne by GSTP1 Hypermi	ethylation.	* Clinical Cancer	
		CHEN et al., "Dermatolibrome is a clonel Volume 27	proliferative disease	" Journal of Cutaneou	s Patholog	зу, 2000, pp. 36-39,	
V		CHEN et al., "Microsatellite alterations in 1996, pp. 1033-1035, Volume 2, No. 9	plasma DNA of sma	cell lung cancer palie	nts," Natu	re Medicine, September	
saminer	T	/Katherine Salmon/		Date		09/30/2008	

E-ANIMER. Initial If reference considered, whether or not clinisten is in conformation with MPEP 809. Down line through classin in not in conformation and state considered, leading to the stort with used commiscialists to suggisted. Application is instruct calcinol consignation number objections. I. See Section 1.5 s

The oblitation of information is incident by 32 CFR 3.6.2 and 3.10. The information is equivaled to aboth no are faith a berriefly, who policiewhich list, his faith of by the ISPFO process) an application. Confidentially is governed by 50 U.S. C. 122 and 37 CFR 1.1. A This collection is estimated to take 2 fours to complete, including gathering, preparing, and submitting the completed application form to the USPFO. Time will vary depending upon the minicipal case, and you comments on the measured of image upon the list below and/or application for reducing this builded, should be sent to the Clark Information Collection 15 of 25 Med 30 This Clark Information Collection 15 of 25 Med 30 This Clark Information Collection 15 of 25 Med 30 This Clark Information Collection 15 of 25 Med 30 This ADDRESS, SEND TO Comment on the order of the Clark Information Collection 15 of 25 Med 30 This ADDRESS, SEND TO Comment on the Clark Information Collection 15 Med 30 This ADDRESS, SEND TO Comment on the Clark Information Clark Information Collection 15 Med 30 This ADDRESS, SEND TO Comment of the Parints, P.O. Ston 1450, Alexandro, IV 22313-1450.

10506693 - GAU: 1634

U.S. Parent and Tradement Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of i Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 6

(Use as many sheets as necessary)

Sheet 3

Complete if Known					
Application Number	10/506,893				
Filling Date	April 21, 2005				
First Named Inventor	Kurt Berlin				
Art Unit	1534				
Examiner Name	Katherine D. Salmon				
Attorney Docket Number	47675-88				

		NON PATENT LITERATURE DOCUMENTS	
xaminer ittials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calatilog, etc.), date, page(s), volume-issue number(s), butterbeher, only andre country where published.	T,
/KS/		DE BUSTROS et al., "The short arm of chromosome 11 is a "not spot" for hypermethylation in human neoplasia," The Proceedings of the National Academy of Science, August 1988, pp. 5693-5697, Volume 65	
		DIVIACCO et al. "A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates," Gene, 1992, pp. 313-320, Volume 122	
		DONG st al., "Promoter Hypermethylason of Multiple Genes in Carcinome of the Uterine Cervix," Clinical Cancer Research, July 2001, pp. 1982-1986, Volume 7	
		EADS et al., "Epigenetic Potterns in the Progression of Esophageal Adenocarcinoma," Cancer Research, April 15, 2001, pp. 3410-3418, Volume 61	
		EISENBERGER et al., "Diagnosis of Renal Cancer by Molecular Urinalysis," Journal of the National Cancer Institute, December 1, 1999, pp. 2028-2032, Volume 91, No. 23	
Т		ESTELLER et at., "A Gene Hypermethylistion Profile of Human Cancer," Cancer Research, April 15, 2001, pp. 3225-3229, Volume 61	
		FEARON et al., "A Genetic Model for Colorectal Tumorigenesis," Cell, June 1, 1990, pp. 759-767, Volume 61	
		FEIL et et, "Methysetion analysis an individual chromosomes: improved protocol for bisulphile genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22, No. 4	
		FERLUGA, "Possible Organ and Age-Related Epigenetic Factors in Huntington's Disease and Coloractal Carcinoma," Medical Hypotheses, 1989, pp. 51-54, Volume 20	
		FOURNIE et al., "Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours." Cancer Letters, 1995, pp. 221-227, Volume 91	
		GARCIA et al., "Loss of p16 Protein Expression Associated with Methylation of the p16 MALA Gens is a Frequent Finding in Hodgkin's Disease." 1999, pp. 1453-1459, Volume 79, No. 12	
		GIACONA et al., "Cell-Free DNA in Human Blood Plasma: Length Measurements in Patients with Pancrestic Cancer and Healthy Controls," Pancress, 1998, pp. 89-97, Volume 17, No. 1	
		GOESSL et al., "Microsatellite Analysis of Plasma DNA from Patients with Clear Cell Renal Carcinoma," Cancer Research, October 15, 1998, pp. 4728-4732, Volume 58	
		GONZALGO et al., "Repid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, Volume 25, No. 12	
		GRIGG et al., "Sequencing 5-Methylocytosine Residues in Genomic DNA," BioEssays, June 1994, pp. 431-436, Volume 16. No. 6	
		HANNA et al., "A Novel Alternative Approach for Prediction of Radiation Response of Squemous Cell Carcinoma of the Head and Neck." Cancer Research, March 15, 2001, pp. 2376-2380, Volume 61	
		HEID et al., "Real Time Quantitative PCR," Genome Research, 1996, pp. 988-994, Volume 6	
V		HENGEN, "Determining DNA concentrations and rescusing PCR primers," Trends in Biochemical Sciences. February 1994, pp. 93-94, Volume 19	

ļ		T	y
Ехаты		Date	09/30/2008
Signati	" /Katherine Salmon/	Considered	*****

The collegion of information is negarized by 3T CFF4 - 6FF and 1-16C. The information is required to obtain our which is broyelf by the public which has Left and by the USPTO to process) an application. Confidentially is governed by \$8 U.S. C. 122 and 37 CFR 1-14. This collection is estimated to base 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the includinal packs. Any comments in the manutual of law sey to require to compete the form and/or suggestions for reducing this burders, stroke the sort in includinal packs. Any comments in the manutual of law sey to require to compete the form and/or suggestions for reducing this burders, stroke the sort in the formation of the sort in the sort in

10506693 - GAU: 1634

Express Mail No EM24516323915
PTO/SERGE, (08-03)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO INFORMATION DISCLOSURE

inder the Paperwork Reduction Act of 1995, no persons are required to n

STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 6

Sheet

gorid to a conscisión de mobilitado	I Unidoo ii kurigatio a valio sviila constat iiditaet.				
Complete if Known					
Application Number	10/506,693				
Filing Date	April 21, 2005				
First Named Inventor	Kurt Berlin				
Art Unit	1634				
Examiner Name	Katherine D. Salmon				
Attorney Docket Number	47675-86				

	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), fille of the item (book, maguzine, journal, serial, symposium, catalos, etc.), date, page(s), volume-issus mumber(s), publisher, oil yardios outrity where published.	T°
/KS/		HENGEN, "Kit Wars." Trends in Biochemical Sciences, January 1994, pp. 48-47, Volume 19	
		HERMAN et at , "Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands," The Proceedings of the National Academy of Sciences, September 1996, pp. 9821-9826, Volume 93	
		MERMAN et al., "Silencing of the VHI, tumor-suppressor gans by DNA methylation in ranal carcinoma," The Proceedings of the National Academy of Sciences, October 1994, pp. 9700-9704, Volume 91	
		HOLLIDAY, "The Inheritance of Epigenetic Defects," Science, October 9, 1987, pp. 163-176, Volume 238	
		HORNSTRA et al., "High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome," Human Molecular Genetics, 1993, pp. 1659-1665, Volume 2, No. 10	
		JAHR et al., "DNA Fragments in the Blood Plasma of Cancer Petients: Quantitations and Evidence for Thair Origin from Apoptolio and Necrolic Cells," Cancer Research, February 15, 2001, pp. 1659-1665, Volume 61	
		JONES, 'DNA Methylation and Cancer," Cancer Research, February 1986, pp. 461-466, Volume 46	
		JONES et al., "The Role of DNA Methylation in Cancer," Advances in Cancer Research, 1990, pp. 1-23, Volume 54	
		KERSTING et al., "Differential Frequencies of pte ^{Wee} promoter Hypermethylation, p53 Mutation, and K-ras Mutation in Exfoliative Material Mark the Development of Lung Canner in Symptomatic Chronic Smokers," Journal of Clinical Oncology, September 15, 2000, pp. 3221-3262, Volume 18, No. 18	
		KLAUCK at at , "Molecular genetic analysis of the FMR-1 gene in a large collection of autistic patients," Human Genetics, 1997, pp. 224-229, Volume 100	
		LABARCA of al., "A Simple, Rapid, and Sensitive DNA Assay Procedure," Analytical Biochemistry, 1980, pp. 344-352, Volume 102	
		LEE et at., "Monoclonal Endothelial Cell Proliferation is Present in Primary but not Secondary Pulmonary Hypertension." Journal of Climical Investigation, March 1998, pp. 927-934, Volume 101, Number 5	
		LEE et al., "Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma," Transfusion, 2001, pp. 276-282, Volume 41	
		LEON et al., "Free DNA in the Serum of Cancer Patients and the Effect of Thorapy," Cancer Research, March 1977, pp. 646-650, Volume 37	
		E.O., "Molecular Testing of Urine: Catching DNA on the Way Out," Clinical Chemistry, 2000, pp. 1039-1040, Volume 46, No 8	
		LO et al., "Quantitative Analysis of Fatal DNA in Materinal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis," American Journal of Human Genetics, 1998, pp. 768-775, Volume 62	
		MACEC, "Plasma DNA Level as a tumor Marker in Primary Lung Cancer," The Japanese Journal of Thorack: Diseases, August 1990, pp. 1085-1091, Volume 28, No. 8	
V		MAKOS et al., "Distinct hypermethylation patterns occur at altered chromosome tool in human lung and colon cancer," The Proceedings of the National Academy of Sciences, March 1992, pp. 1929-1933, Volume 89	

	······································	
Examiner Signature /Katherine Salmon/	Date Considered	09/30/2008

EXAMINER: Initial it reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation with MPEP 609. Examence: impast a reservoir cursus-steet, vinceiner or not collaport is a conformation with memory of using or set influing collaport in fact in conformation and not considered. Intakine steep of this form with met commencation is applicant. Applicant is usuage costation designation number opposition. If see Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPP 991.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the document, by the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Available code (MPP 091.04 "Ener Office that squed the Availabl document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This editation of information is required by 37 CFR 1.97 and 1.92. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10506693 - GAU: 1634 Express Molt No.EM245163238US

Approved for use through 07/31/2006 OMB 0851-0031
U.S. Patent and Traderrank Office. U.S. DEPARTMENT OF COMMERCE
o a ordination of information united it commisses a visit of OMB control united in united in the control of the contro

47875-86

Substitute for form 1449/PTO	Complete if Known			
INFORMATION DISCLOSURE	Application Number	10/506.693		
	Filing Date	April 21, 2005		
STATEMENT BY APPLICANT	First Named Inventor	Kurt Berlin		
(Use as many sheets as necessary)	Art Unit	1634		
	Examiner Name	Katherine D. Salmon		

Attorney Docket Number

Sheet

αf

Examiner Cite		Include name of this author (in CAPITAL LETTERS), title of the article (when appropriate), title of this item (book, magazine, journal, serial, symposium, catalog, etc.), take, pagets), volume-i-souré	
nituats*	No.1	number(s), publisher, city and/or country where published.	T2
/KS/		MAC et al., "Detection of Oncogene Mutations in Sputum Precedes Diagnosis of Lung Cancer," Cancer Research, April 1, 1994, pp. 1634-1637, Volume 54	
L		MAO, "Senetic Alterations as Clonal Markers for Bladder Cancer Detection in Unine," Journal of Celtular Biochemistry, 1996, pp. 191-198, Volume 25S	
		MAO et at., "Microsate/like afterations as clonal markers for the detection of human cancer," The Proceedings of the Netional Academy of Sciences, October 1994, pp. 9871-9875, Volume 91	
		MARTIN et at., "Genomic sequencing indicates a cometation between DNA hypomethylation in the 5' region of the p\$2 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 281-264, Volume 157	
Т		MARLIYAMA et al., "Aberrant Promoter Methylation Profite of Bladder Cancer and its Relationship to Clinicopathological Features," Cancer Research, December 15, 2001, pp. 8659-8683, Volume 61	
		NAKAO et al., "Repid and Reliable Quantification of filinmat Residual Disease in Azute Lymphoblastic Leukemia Using Rearranged Immunoglobin and T-Cell Receptor Loci by LightCycler Technology," Cancer Research, June 15, 2000, pp. 3261-3289. Volume 60	
		OHTANI-FLUITA et al., "CpG methylation inactivates the promoter activity of the human retinoblastoms humor- suppressor gene," Oncogene, 1993, pp. 1053-1067, Volume 8	
		OLEK et at., "A modified and improved method for bisulphite based cytosine methylation analysis." Nucleic Acids Research, 1996, pp. 5084-5066. Volume 24, No. 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methytation impant," Nature Genetics, November 1997, pp. 275-276, Volume 17	
		PALMISANO et at., "Predicting Lung Cancer by Detecting Aberrant Promoter Methylation in Sputum," Cancer Research, November 1, 2000, pp. 5954-5958, Volume 60	
		REIN et at, "Identifying 5-methytcytosine and related modifications in DNA genomes," Nucleic Acids Research, 1998, pp. 2255-2264, Volume 28, No. 10	
		SACCOMANNO et al., "Development of Carcinoma of the Lung as Reflected in Exfoliated Cells," Cancer, January 1974, pp. 266-270, Volume 33	
		SANCHEZ-CESPEDES et al., "Gens Promoter Hypermethylation in Tumors and Senum of Head and Neck Cancer Patients," Cancer Research, February 15, 2000, pp. 892-895, Volume 60	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," The Proceedings of the National Academy of Sciences, December 1977, pp. 5463-5467, Volume 74, No. 12	
		SHAPIRO et al., "Determination of Circulating DNA Levels in Patients with Benign or Malignant Gastrotniestinal Disease," Cancer, 1983, pp. 2116-2120, Volume 51	
V		SHAPIRO et al., "Specific Deamination of RNA by Sodium Bisulphite," Nature, September 5, 1970, pp. 1047-1048, Volume 227	
V	T	SORENSON et al., "Soluble Normal and Mutatad DNA Sequences from Single-Copy Genes in Human Blood," Cancer Epidemiology, Biomarkers & Prevention, January/February 1994, pp. 67-71, Volume 3	

Examiner Signature /Katherine Salmon/ Date Considered 09/30/2008

EXAMINET: Initial if reference considered, whether or not classins is in conformation with IMPP 900. There like through classins if not in conformation and and conformation in preparability. Applicant is subject classification of the conformation in the conformation

To complete the design of the state of the s

10506693 - GAU: 1634 Express Mail No.EM245163239US

Approved for use mrough 97/31/206 OMB 981-981 B.S. Pakeni and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to r

INFORMATIO	N D	ISCL	osi	JRE
STATEMENT	RY	APPI	IC.A	NT

1 6

(Use as many sheets as necessary) of

Substitute for form 1449/PTO

Sheet

Complete if Known						
Application Number	10/506,693					
Filing Date	April 21, 2005					
First Named Inventor	Kurt Berlin					
Art Unit	1634					
Examiner Name	Katherine D. Salmon					
Attorney Docket Number	47675-86					

kaminer itiais*	Citte No.	Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), file of the Item (book, magazine, journal, serial, symposium, calalies, etc.), date, page(s), volume-issue number(s), subtheter, orly androcountry where published.	T°
/KS/		TUCK-MULLER et at, "ONA hypomethylasion and unusual chromosome instability in cell lines from ICF syndrome patients," Cytogenetics and Cell Genetics, 2000, pp. 121-128, Volume 89	
		USADEL et al., "Quantitative Adenomatous Polyposis Coli Promoter Methylation Analysis in Tumor Tissue, Serum, and Plasma DNA of Patients with Lung Cancer, Cancer Research, January 15, 2002, pp. 371-375, Volume 52	
		WONG et al., "Detection of Aberrant p16 Methylation in the Plasma and Serum of Liver Cancer Patients," Cancer Research, January 1, 1999, pp. 71-73, Volume 59	
		WONG et al., *Frequent p15 Promoter Methylation in Tumor and Perigheral Blood from Hepatoositular Cardinome Patients,* Clinical Cancer Research, September 2000, pp. 3516-3521, Volume 6	
		Will at at, "Loss of Heterozygosity of the Putative Prostate Cancer Susceptibility Gene MPC2/ELAC2 ts Uncommon in Sporadic and Familial Prostate Cancer," Cancer Research, December 15, 2001, pp. 8651-8653, Volume 61	
		XIONG et al. "COBRA: a sensitive and quantitative DNA methylation assay," Nucleic Acids Research, 1997, pp. 2532- 2534, Volume 25, No. 12	
		YANAGISAWA et al., "Nethylation of the hMLH1 Promoter in Familial Gastric Cancer with Microsatellite Instability." International Journal of Cancer, 2000, pg. 50-53, Volume 65	
		YU et at., "Specific Inhibition of PCR by Non-Extendable Ofigenucleofides Using a 5' to 3' Exonuclease-Deficient DNA Polymerase," BioTechniques, October 1997, pp. 714-720, Volume 23	
		ZESCHNIGK et al., "Imprinted segments in the human genome: different DNA methylstion pattersn in the Preder-Willi/ Angelman syndrame region as determined by the genomic sequencing method," Human Molecular Genetics, 1997, pp. 367-398, Volume 9, No. 3	
$\overline{\Psi}$		ZESCHNIGK at al., "A single-lube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus," European Journal of Human Genetics, March-April 1997, pp. 94-98, Volume 5, No.	
	-		
	 		

Examiner Signature: /Katherine Salmon/ Date Considered	09/30/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include compy of this from with next communicable in a spitiant. In a spitiant is unique citation designation unique citation designation unique citation designation unique citation designation and the citation designation

document. Yield of document by the appropriate symbols as molecular or use concerns when the English impuges frankfall in state of a chord man here. English impuges frankfall in state of a chord man here. English can be supported by \$1.7 to state of \$1.7 to state of the chord is chord in the state of \$1.7 to state of the chord in the chord in the state of the chord in the chord i (and by the USPF10 to process) an application. Confidentiship is governed by 30 U.S.C. 172 and 37 C.P.K. 133. This Collection is estimated to laws 2 combine to complete, including pitch register, and in the USPF10. The real sivery depending upon the the Chief Information Office, U.S. Patient and Thiodemark Office, U.S. Department of Commission. P.O. Box 1450, Alexandrus, V.A. 22315-1450. DO NOT. SERVO PEERS OF COMPRETED FORMS TO THIS ADDRESS, SEND TO. Commissioner for Patients, P.O. Box 1450, Alexandrus, V.A. 22315-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.